Nektar Therapeutics

Nektar Therapeutics is a clinical-stage biotechnology company developing first-in-class therapeutic candidates for autoimmune and inflammatory diseases. Its approach combines proprietary PEGylation technology with immune science, with a particular focus on regulatory T cell biology. The company was founded in 1990.

Work at Nektar spans several technical domains, including PEGylation technology, immunology and immune science, regulatory T cell biology, medicinal chemistry, oncology, virology and broader drug development. Its industry activities sit across biotechnology, pharmaceuticals, autoimmune disease, oncology, virology and immunology.

The company describes its culture as guided by scientific ingenuity, with an emphasis on pursuing big scientific questions through unique approaches and on first-in-class, disease-modifying therapeutic candidates. Its stated orientation is toward transformative impact for patients with autoimmune diseases and chronic inflammation.